Woodward Diversified Capital LLC Acquires New Shares in Gilead Sciences, Inc. $GILD

Woodward Diversified Capital LLC acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, according to its most recent filing with the SEC. The fund acquired 2,856 shares of the biopharmaceutical company’s stock, valued at approximately $317,000.

A number of other institutional investors have also added to or reduced their stakes in GILD. Brighton Jones LLC grew its position in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after buying an additional 2,450 shares during the last quarter. Bison Wealth LLC bought a new position in shares of Gilead Sciences in the 4th quarter worth approximately $215,000. NBC Securities Inc. lifted its stake in shares of Gilead Sciences by 60,592.9% in the 1st quarter. NBC Securities Inc. now owns 8,497 shares of the biopharmaceutical company’s stock valued at $952,000 after purchasing an additional 8,483 shares during the period. Merit Financial Group LLC lifted its stake in shares of Gilead Sciences by 48.3% in the 1st quarter. Merit Financial Group LLC now owns 29,229 shares of the biopharmaceutical company’s stock valued at $3,275,000 after purchasing an additional 9,522 shares during the period. Finally, HBW Advisory Services LLC lifted its stake in shares of Gilead Sciences by 8.4% in the 1st quarter. HBW Advisory Services LLC now owns 3,365 shares of the biopharmaceutical company’s stock valued at $377,000 after purchasing an additional 262 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on GILD. Royal Bank Of Canada raised their target price on Gilead Sciences from $96.00 to $98.00 and gave the company a “sector perform” rating in a research note on Friday, August 8th. UBS Group raised their price objective on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research report on Friday, August 8th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Needham & Company LLC raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a report on Friday, July 25th. Finally, JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, September 16th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $117.17.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction on Monday, July 28th. The stock was sold at an average price of $113.94, for a total value of $1,139,400.00. Following the transaction, the chief executive officer directly owned 605,725 shares of the company’s stock, valued at $69,016,306.50. This represents a 1.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the sale, the chief financial officer directly owned 159,555 shares in the company, valued at $18,120,661.35. This represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 82,000 shares of company stock valued at $9,402,130 in the last quarter. Insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 0.1%

Shares of NASDAQ GILD opened at $111.15 on Thursday. The company has a debt-to-equity ratio of 1.13, a quick ratio of 1.15 and a current ratio of 1.32. The firm has a market capitalization of $137.92 billion, a price-to-earnings ratio of 22.14, a PEG ratio of 0.75 and a beta of 0.34. The stock has a 50 day moving average price of $114.47 and a 200 day moving average price of $109.92. Gilead Sciences, Inc. has a 52-week low of $83.10 and a 52-week high of $121.83.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The company had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences’s revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Investors of record on Monday, September 15th were given a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio is presently 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.